BMC Cancer

Table 1 Breast and ovarian cell lines used in this study and their sensitivity to V158411

From: Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Tissue	Cell line	Gene cluster	ER	PR	HER2	TP53	GI₅₀(μM)
Breast	BT474	Lu	+	+	+	Mut	2.6 ± 1.3
	HCC1937	BaA	-	-		Mut	0.11 ± 0.01
	MCF7	Lu	+	+		WT	2.0 ± 0.5
	MDA-MB-157	BaB	-	-		Mut	0.25 ± 0.02
	MDA-MB-231	BaB	-	-		Mut	0.18 ± 0.02
	MDA-MB-453	Lu	-	-		WT	0.019 ± 0.005
	MDA-MB-468	BaA	-	-		Mut	0.31 ± 0.02
	SKBr3	Lu	-	-	+	Mut	0.022 ± 0.003
Ovarian	A2780		-		-	WT	0.39 ± 0.05
Ovarian	ES-2					Mut	3.1 ± 1.2
	SKOV-3		-		+	Mut	0.06 ± 0.02

ER, estrogen receptor; PR, progesterone receptor; BaA, Basal A; BaB, Basal B; Lu, Luminal; WT, wild type; Mut, mutant; breast data from [31]. Values represent the mean ± SD of n ≥ 4.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com